Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

19.82 -0.05 (-0.25%)
Official Closing Price Updated: 1:15 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 852,288
Open 19.99
Bid (Size) 19.91 (100)
Ask (Size) 20.41 (100)
Prev. Close 19.87
Today's Range 19.71 - 20.20
52wk Range 8.580 - 20.20
Shares Outstanding 69,484,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga

Performance

YTD
+40.8%
+40.8%
1 Month
+48.0%
+48.0%
3 Month
+23.0%
+23.0%
6 Month
+80.5%
+80.5%
1 Year
+18.5%
+18.5%

More News

Read More
News headline image
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 3, 2025 ↗
Via Benzinga
News headline image
Syndax Pharmaceuticals's Earnings Outlook ↗
Via Benzinga
SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 4, 2025 ↗
Via Benzinga
News headline image
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Announces Participation in November Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Is Syndax Stock Down Today? ↗
Via Benzinga
News headline image
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Where Syndax Pharmaceuticals Stands With Analysts ↗
Via Benzinga
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗
Via Benzinga
News headline image
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
Via Benzinga
News headline image
Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗
Via Benzinga
News headline image
Syndax Announces Participation in September Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Syndax (SNDX) Q2 Revenue Jumps 986% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss ↗
Via Chartmill
News headline image
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?
Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market
What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?
The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 19.82
When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 11/28/25 01:15 PM ET
What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.38B
How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?
Syndax Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback